Palantir jumps 17% on report of $44 million FDA contract
December 7, 2020 | Uncategorized
The deal is worth $44.4 million and will focus on powering drug reviews and inspections, according to the report.
The deal is worth $44.4 million and will focus on powering drug reviews and inspections, according to the report.
